ABBOTT PARK, Ill., Nov. 22 /PRNewswire/ -- Abbott Laboratories today announced it has acquired certain assets of Glaxo Wellcome Inc.'s anesthesia business in the United States. Financial terms of the agreement were not disclosed. Included in the acquisition are four neuromuscular blockers (muscle relaxants) and Ultiva(R) (remifentanil), an ultra-short acting analgesic. Abbott obtains rights to the related trademarks, intellectual property, clinical data, regulatory files and manufacturing know-how pertaining to the products. "These products are an excellent fit with our current perioperative and intensive care product offerings. Today's agreement enhances an already extensive line of Abbott anesthesia products for our customers," said Richard A. Gonzalez, senior vice president, hospital products. "Each of these products can be used in conjunction with our inhaled anesthesia agents and are well suited for use in the growing ambulatory surgery setting." The four neuromuscular blockers include three proprietary products, Nimbex(R) (cisatracurium), Mivacron(R) (mivacurium) and Nuromax(R) (doxacurium), as well as Tracrium(R) (atracurium). All four products are used as adjuncts to general anesthesia but work for varying lengths of time. The products can be used prior to surgery to ease endotracheal intubation and during surgery to facilitate skeletal muscle relaxation and mechanical ventilation. Ultiva(R) (remifentanil) is the first in a class of ultra-short acting analgesics known as esterase opioids and is used in surgical, post surgical and monitored anesthesia cases (when patients are awake during a surgical procedure). With a very rapid onset and offset of action and an ease of control by the clinician, the use of Ultiva(R) allows for repeated or prolonged administration without the risk of drug accumulation and the associated side effects of other opioids. Abbott's perioperative and intensive care product line offers a proven product for every phase of the anesthesia procedure from pre-medication, through surgery and recovery and post-operative pain management. Products in this franchise include inhalation and induction agents, local anesthetics, analgesics and muscle relaxants. The sale of these products is supported by one of the largest, hospital-based specialty sales forces focusing exclusively on anesthesiologists and nurse anesthetists. Abbott, a world leader in anesthesia products for more than 75 years, manufactures and markets a broad range of anesthesia and pain management products. These products include highly successful products like Penthothal(R), launched more than 50 years ago and still an important induction anesthetic; the first patient-controlled analgesia (PCA) system in the United States; the first transmucosal drug delivery system for pediatric and adult anesthetic premedication; the co-promotion of Anzemet(R), an antiemetic for post-operative nausea and vomiting, and OxyContin(TM) for post-operative pain; and Ultane(R) (sevoflurane), the leading inhalation agent for pediatric and adult patients. Abbott Laboratories is a global, diversified health care company devoted to the discovery, development, manufacture and marketing of pharmaceutical, diagnostic, nutritional and hospital products. The company employs 56,000 people and markets its products in more than 130 countries. In 1998, the company's sales and net earnings were $12.5 billion and $2.3 billion, respectively, with diluted earnings per share of $1.51. Abbott's news releases and other information are available on the company's Web site at www.abbott.com .
SOURCE Abbott Laboratories